Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00065429 · ClinicalTrials.gov registry record · Phase 1
Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer
A Phase 1 study, sponsored by ImmunoGen.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT00065429 is a Phase 1 study that has completed, run by ImmunoGen. The registered enrollment target is 64 participants.
The verdict
NCT00065429, a Phase 1 study, has completed, sponsored by ImmunoGen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This study was a Phase I/II trial primarily focused on efficacy of BB-10901 in relapsed small cell lung cancer and other solid tumors.
Interventions
- DRUG BB-10901
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2003-04 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00065429
The ClinicalTrials.gov registry entry for NCT00065429 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunoGen, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BB-10901 is the first listed.
NCT00065429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00065429 about?
NCT00065429 is a clinical study titled "Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer". This study was a Phase I/II trial primarily focused on efficacy of BB-10901 in relapsed small cell lung cancer and other solid tumors.
What is the current status of trial NCT00065429?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2003-04. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00065429?
The interventions under investigation include: BB-10901 (DRUG).
Who is sponsoring clinical trial NCT00065429?
This trial is sponsored by ImmunoGen, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.